The Mechanism and Utility of CPI-613 for the Treatment of Hematologic Malignancies

February 6, 2014
Timothy S. Pardee, MD

Timothy S. Pardee, MD, from Wake Forest University Baptist Medical Center, discusses the mechanism and utility of the pyruvate dehydrogenase complex inhibitor CPI-613 for the treatment of patients with advanced hematologic malignancies.

Clinical Pearls

Timothy S. Pardee, MD, assistant professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, discusses the mechanism and utility of the pyruvate dehydrogenase complex inhibitor CPI-613 for the treatment of patients with advanced hematologic malignancies.

  • A phase I study is analyzing the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies
  • CPI-613 attacks cancer cells by hitting the mitochondria, which alters the ability of the cells to make the building blocks of the next cancer cell
  • In the trial, 40% of the 21 evaluable and heavily-pretreated patients responded
  • There was some evidence of acute renal failure, nausea, and diarrhea associated with the trial, though no myelosuppression was observed